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Abstract
Background: Accurately identifying individuals who are on antiretroviral therapy (ART) is important to determine
ART coverage and proportion on ART who are virally suppressed. ART is also included in recent infection testing
algorithms used to estimate incidence. We compared estimates of ART coverage, viral load suppression rates and
HIV incidence using ART self-report and detection of antiretroviral (ARV) drugs and we identified factors associated
with discordance between the methods.
Methods: Cross-sectional population-based survey in KwaZulu-Natal, South Africa. Individuals 15–59 years were
eligible. Interviews included questions about ARV use. Rapid HIV testing was performed at the participants’ home.
Blood specimens were collected for ARV detection, LAg-Avidity HIV incidence testing and viral load quantification
in HIV-positive individuals. Multivariate logistic regression models were used to identify socio-demographic
covariates associated with discordance between self-reported ART and ARV detection.
Results: Of the 5649 individuals surveyed, 1423 were HIV-positive. Median age was 34 years and 76.3% were women.
ART coverage was estimated at 51.4% (95%CI:48.5–54.3), 53.1% (95%CI:50.2–55.9) and 56.1% (95%CI:53.5–58.8) using
self-reported ART, ARV detection and both methods combined (classified as ART exposed if ARV detected and/or ART
reported) respectively. ART coverage estimates using the 3 methods were fairly similar within sex and age categories
except in individuals aged 15–19 years: 33.3% (95%CI:23.3–45.2), 33.8% (95%CI:23.9–45.4%) and 44.3% (95%CI:39.3–46.7)
using self-reported ART, ARV detection and both methods combined. Viral suppression below 1000cp/mL in individuals
on ART was estimated at 89.8% (95%CI:87.3–91.9), 93.1% (95%CI:91.0–94.8) and 88.7% (95%CI:86.2–90.7) using
self-reported ART, ARV detection and both methods combined respectively. HIV incidence was estimated at 1.4
(95%CI:0.8–2.0) new cases/100 person-years when employing no measure of ARV use, 1.1/100PY (95%CI:0.6–1.7)
using self-reported ART, and 1.2/100PY (95%CI:0.7–1.7) using ARV detection. In multivariate analyses, individuals aged
15–19 years had a higher risk of discordance on measures of ARV exposure (aOR:9.4; 95%CI:3.9–22.8), while migrants
had a lower risk (aOR:0.3; 95%CI:0.1–0.6).
Conclusions: In KwaZulu-Natal, the method of identifying ARV use had little impact on estimates of ART coverage, viral
suppression rate and HIV incidence. However, discordant results were more common in younger individuals. This may
skew estimates of ART coverage and viral suppression, particularly in adolescent surveys.
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Background
Accurately identifying individuals who are on antiretro-
viral therapy (ART) in HIV surveys is important to de-
termine ART coverage and the proportion of those on
ART who are virally suppressed. In addition, antiretro-
viral (ARV) use is often included in recent infection test-
ing algorithms (RITAs) used to estimate incidence, to
ensure that patients on ART are not misclassified as
recently infected.
ART exposure can be identified by including questions
on prior and current ART use in survey questionnaires
(self-report), or by detection of antiretroviral drugs
(ARVs) in blood. Self-report has commonly been used in
surveys to identify individuals on ART [1–5] but accur-
acy cannot be verified without an objective measure.
ARV detection in dried blood spots (DBS) is an objective
method to identify patients with recent ART exposure,
but may not identify individuals on ART who have poor
or irregular adherence to ART.
We used data from a population-based HIV survey
conducted in Mbongolwane and Eshowe, KwaZulu-
Natal (KZN), South Africa [6]. In this analysis we
compared estimates of ART coverage and viral load
suppression rates when we used self-report and/or ARV
detection to identify individuals on ART. We assessed
the agreement between the two methods of identifying
individuals on ART and the socio-demographic covari-
ates associated with discordance between ART self-
report and ARV detection. Finally, we determined the
impact of including ART use, as ascertained by these
two methods, on HIV incidence estimation.
Methods
Design and population
This study is part of a cross-sectional population-based
survey conducted from July to October 2013 that aimed
to assess HIV prevalence, incidence and the HIV cascade
of care in Mbongolwane and Eshowe, KZN, [6]. Individ-
uals aged 15–59 years old living in the area were eligible
for inclusion in the survey.
Procedures
Participants were interviewed at home using a struc-
tured questionnaire. Interviews were carried out in an
isolated part of the dwelling to preserve confidentiality.
We collected socio-demographic information and his-
tory of HIV clinical care. The questionnaire included
three questions about whether or not the participant
was on ART: ‘Have you ever initiated ART, antiretro-
viral drugs against HIV/AIDS?’, ‘When did you first
start antiretroviral drugs?’, ‘Are you still receiving anti-
retroviral drugs?’ HIV testing was performed at the
participants’ home using the Determine Rapid HIV-1/2
Antibody test kit, as a screening test, followed by the
Unigold Rapid HIV test kit. HIV-positivity was con-
firmed by ELISA. Venous blood specimens were col-
lected for single-well limiting antigen avidity enzyme
immunoassay (LAg-Avidity EIA) and Nucleic Acid
Amplification Testing (NAAT). DBS were prepared at
the laboratory to test for the presence of ARVs. We
performed qualitative testing for the presence of nevi-
rapine, efavirenz and lopinavir by liquid chromatog-
raphy tandem mass spectrometry with a limit of
quantification of 0.04 micrograms/ml for all drugs.
The median time window from last drug intake to a
negative detection depends on the drug and ranges
from around 24 h for lopinavir up to 7 days for efavir-
enz and nevirapine [7–9]. Viral load was quantified
using a NucliSens EasyQ HIV-1 v2.0 assay from Bio-
merieux. NAAT testing was performed on 5 member
pools using Roche AMPLISCREEN, with positive pools
reflexed to individual specimen testing using the Roche
CAP/CTM method. HIV-1 genotyping was carried out
at the Centre for AIDS Prevention and Research in
South Africa (CAPRISA) on samples from participants
on ART with viral load higher than 1000 copies/ml,
using the TRUGENE HIV-1 Genotyping assay from
Siemens Healthcare Diagnostics. Genotypic resistance
was interpreted according to the Stanford University
algorithm for HIV drug resistance.
Definitions
Self-reported ART: Individuals who reported that they
had “ever initiated ART” and were “still receiving ART”.
ARV detected: Nevirapine, efavirenz or lopinavir
detected in DBS.
Combined method to identify ART exposure: Catego-
rized as on ART if either ART was self-reported or ARV
was detected.
ART discordance: Individuals identified as on ART by
one measure but not the other. There were 2 categories
of discordance: 1. Individuals who reported being on
ART but had no detectable ARV (these likely represent
individuals on ART with irregular adherence who did
not take any ART in the 24 h before, with a longer win-
dow for efavirenz). 2. Individuals in whom an ARV was
detected who did not report taking ART (these are likely
individuals who chose not to disclose being on ART).
ART coverage among all HIV-positive individuals: pro-
portion of HIV-positive individuals on ART among all
HIV-positive individuals.
ART coverage among individuals qualifying for ART:
proportion of HIV-positive individuals on ART among
individuals whether already on ART or qualifying for
ART. Criteria for initiation of ART by National Guide-
lines at the time of the survey were: CD4 < 350cells/μl,
pregnant and breastfeeding women.
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Viral load suppression rate: viral load below 1000 cp/mL
among those identified as being on ART.
Mobility categories: Resident: individuals belonging
to the household who had not moved their residency
in the previous 10 years. Migrant: individuals belong-
ing to the household who had moved their residency in
the previous 10 years. Visitor: individuals not belong-
ing to the household who slept in the household the
night before the day of the interview.
Data analyses
Descriptive analyses are presented with 95% confi-
dence intervals (95%CI). Three estimates of ART
coverage and viral suppression were calculated using
self-reported ART, ARV detection and the combined
method to identify ART exposure. HIV incidence was
calculated by the method of Kassanjee et al. [10]. The
case definition for ‘recent infection’ was: either acute
infection (antibody negative but NAAT positive) or re-
cent on the compound rule of LAg-Avidity EIA nor-
malized optical density below 1.5, viral load above 100
cp/mL and not on ART. Three estimates of HIV inci-
dence were calculated: employing no measure of ART
use and employing either self-reported ART or ARV
detection to identify the individuals not on ART. We
estimated Mean Duration of Recent Infection (MDRI)
for this RITA at 184 days (95% CI: 159–219), based on
a subtype C-specific estimate for the LAg-Avidity EIA
and the sensitivity of the screening algorithm [11]. The
False Recent Rate (FRR) was estimated in a similar
context at 0.2% [12].
Interrater agreement (kappa, ƙ) was used to quantify
agreement between self-report and ARV detection.
Multivariate logistic regressions were used to explore
associations between participant characteristics and
discordance between self-reported ART and ARV de-
tection with 3 outcomes: (1) ARV detected and not
self-reported, (2) ART self-reported and not detected,
(3) any ART discordance (ARV detected and not
reported or ART reported and not detected). Factors
included in the model were: sex (women, men), age
(15–19, 20–34, 35–44, 45–59 years), marital status
(never married, married/living together, divorced/sepa-
rated/widowed), level of education (primary or less,
secondary or more), area of residence (urban, rural),
mobility (resident, migrant, visitor) and employment
(employed, not employed). After selecting factors asso-
ciated with discordance with p < 0.25 in the univariate
analyses, we applied a step-wise decreasing strategy to
select the variables in the multivariate analyses. Sex,
age and variables with p-value < 0.10 were kept in the
final model. Data were analyzed using Stata 13 (Stata
Corp., College Station, Texas, USA). Incidence analyses
were performed using the inctools R package [13].
Results
Description of the survey population
The survey included 5649 individuals of which 1423
were found to be HIV-positive. Median age of HIV posi-
tive participants was 34 years (IQR: 27–42) and 1085
(76.3%) were women, 345 (24.3%) lived in couple, 686
(48.2%) had completed at least secondary education,
1142 (80.3%) lived in rural areas, 225 (15.8%) were mi-
grants, 711 (50.0%) were unemployed (Table 1).
ART coverage estimates
ART coverage among all HIV-positive individuals was
estimated at 51.4% (95%CI: 48.5–54.3) of HIV-positive
individuals using self-reported ART, 53.1% (95%CI:
50.2–55.9) using ARV detection and 56.1% (95%CI:
53.5–58.8) using with both methods combined (Table 2).
ART use was reported by 712/1385 of HIV-positive indi-
viduals who completed the structured questionnaire. Of
1396 with specimens tested, 741 had ARVs detected in
Table 1 Socio-demographic characteristics of the HIV-positive
participants
Women Men Total
(N = 1085) (N = 338) (N = 1423)
n (%) n (%) n (%)
Age, years
15–19 58 (5.4) 12 (3.6) 70 (4.9)
20–34 537 (49.5) 140 (41.4) 677 (52.5)
35–44 281 (25.9) 105 (31.1) 386 (27.1)
45–59 209 (19.3) 81 (24.0) 290 (20.4)
Marital Status
Never Married 753 (69.4) 236 (70.0) 989 (69.6)
Married/Living Together 265 (24.4) 80 (23.7) 345 (24.3)
Divorced/Separated/Widowed 67 (6.2) 21 (6.2) 88 (6.2)
Education
No schooling 96 (8.9) 31 (9.2) 127 (8.9)
Primary 448 (41.3) 161 (47.8) 609 (42.8)
Secondary 513 (47.3) 137 (40.7) 650 (45.7)
Tertiary 28 (2.6) 8 (2.4) 36 (2.5)
Place residence
Urban 202 (18.6) 79 (76.6) 281 (19.8)
Rural 883 (81.4) 79 (23.4) 1142 (80.3)
Mobility
Residents 876 (80.7) 265 (78.4) 1141 (80.2)
Migrants 170 (15.7) 55 (16.3) 225 (15.8)
Visitors 39 (3.6) 18 (5.3) 57 (4.0)
Occupation
Employed 520 (47.9) 192 (56.8) 712 (50.0)
Not employed 565 (52.1) 146 (43.2) 711 (50.0)
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DBS. Combining the two methods we calculated that
798/1423 participants were on ART.
ART coverage among people qualifying for ART at the
time of the survey was estimated at 74.8% (95%CI: 71.7–
77.6) using self-reported ART, 75.0% (95%CI: 72.0–77.8)
using ARV detection and 78.1% (95%CI: 75.2–80.7)
using with both methods combined. ART coverage esti-
mates using the 3 methods were generally fairly similar
within sex and age categories except in individuals aged
15–19 years. In this age group, coverage was higher
when both methods were combined, compared to the
estimates by ARV detection or by self-report alone, al-
though this difference was not statistically significant.
Using any of the 3 methods, ART coverage was higher in
individuals aged 35–59 years compared to those aged
15–34 years (p < 0.001 for all 3 methods).
Of those with ARV detected, 581 (78.4%) were on
efavirenz-containing ART, 105 (14.2%) on nevirapine-
containing ART, and 61 (8.2%) on lopinavir-containing
ART. In 6 patients more than one drug was detected: 3
with nevirapine and lopinavir, 2 with nevirapine and
efavirenz, 1 with efavirenz and lopinavir.
Viral suppression estimates and HIV-1 ARV resistance mutations
Viral suppression rates in individuals on ART was 89.8%
(95%CI: 87.3–91.9) using self-report, 93.1% (95%CI:
91.0–94.8) using ARV detection and 88.7% (95%CI:
86.2–90.7) with both methods combined, respectively
(Table 3). Viral suppression was lower in individuals
who reported being on ART but who had no ARV
detected, 25.0% (13/52) compared to participants who
did not report ART but had ARV detected, 70.2% (40/
57). Among the 30 individuals aged 15–19 years with
ART reported or ARVs detected, 8 reported being on
ART but ARV were not detected and in 7 individuals
ARVs were detected but not reported. Thus, in individ-
uals aged 15–19 years, viral suppression was lower
among those who reported being on ART than among
those in whom ARV was detected: 56.5% (95%CI: 35.6–
75.4) vs 87.0% (95%CI: 63.9–95.2).
Resistances tests were performed in the 54 patients
who reported being on ART for more than 6 months
and had viral load greater than 1000 copies/mL. Among
the participants who reported ART, 61.1% (33/54) had at
least one resistance mutation while this proportion
Table 2 ART coverage estimates by sex and age using self-report, ARV detection in DBS and both methods combined among all
HIV-positive individuals and among individuals qualifying for ART by National Guidelines at the time of the survey
Self-report ARV detection Combined measurea
% (95%CI) % (95%CI) % (95%CI)
All HIV-positive 51.4 (48.5–54.3) 53.1 (50.2–55.9) 56.1 (53.5–58.8)
Women 52.6 (49.5–55.6) 55.4 (52.5–58.2) 57.8 (54.9–60.7)
Men 47.7 (41.2–54.3) 45.8 (39.9–51.8) 50.6 (44.4–56.8)
15–19 years 33.3 (23.3–45.2) 33.8 (23.9–45.4) 44.3 (33.0–56.2)
20–34 years 37.2 (33.6–41.0) 41.1 (37.3–44.9) 43.0 (39.3–46.7)
35–44 years 67.8 (62.6–72.6) 67.6 (62.7–72.2) 72.5 (67.8–76.8)
45–59 years 66.6 (61.5–71.2) 66.1 (60.6–71.2) 67.6 (62.4–72.4)
Qualifying for ARTb 74.8 (71.7–77.6) 75.0 (72.0–77.8) 78.1 (75.2–80.7)
Women 77.8 (75.0–80.5) 78.5 (75.8–81.0) 81.1 (78.5–83.5)
Men 65.7 (58.1–72.5) 63.9 (56.6–70.5) 68.7 (61.4–75.2)
15–19 years 63.9 (47.6–77.5) 59.0 (42.1–74.0) 73.8 (58.6–84.9)
20–34 years 62.3 (57.5–66.9) 64.8 (60.1–69.2) 67.4 (62.8–71.6)
35–44 years 85.3 (80.1–89.3) 84.8 (80.0–88.7) 88.6 (84.0–92.0)
45–59 years 84.1 (79.2–88.1) 83.6 (78.0–88.1) 84.5 (79.2–88.6)
aCombined measure: categorized as ART exposed by at least one method
bIndividuals qualifying for ART by National Guidelines at the time of the survey: initiated on ART, not on ART with CD4 < 350cells/μl,
pregnant and breastfeeding women
Table 3 Viral suppression below 1000 cp/mL by sex and age
using self-report, ARV detection and both methods combined
among HIV-positive individuals on ART
Self-report ARV detection Combined measurea
% (95%CI) % (95%CI) % (95%CI)
Women 90.4 (87.7–92.6) 93.4 (91.1–95.1) 89.6 (87.1–91.6)
Men 87.7 (81.5–92.1) 92.1 (86.0–95.7) 85.2 (78.9–89.9)
15–19 years 56.5 (35.6–75.4) 87.0 (63.9–95.2) 67.7 (49.5–81.8)
20–34 years 88.0 (83.4–91.5) 91.5 (86.9–94.6) 86.9 (82.2–90.4)
35–44 years 89.8 (85.1–93.1) 92.6 (88.6–95.3) 87.8 (83.3–91.2)
45–59 years 96.6 (92.5–98.2) 96.8 (93.2–98.6) 95.9 (92.0–97.9)
All individuals 89.8 (87.3–91.9) 93.1 (91.0–94.8) 88.7 (86.2–90.7)
aCombined measure: at least one method determining positive ART exposure
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increased to 72.4% (21/29) in individuals who had ARVs
detected. There were NNRTI resistance mutations in
31/54 (57.4%), NRTI mutations in 25/54 (46.3%) and PI
mutations in 5/62 (9.3%) (Additional file 1: Table S1).
Among the participants with reported ART and no
ARVs detected, 48.0% (12/25) had at least one resist-
ance mutation: 7 to NRTIs, 10 to NNRTIs and 4 to PIs.
Among participants taking NNRTI’s as per blood test,
74.1% (20/27) had a positive resistance test to any of
the drugs in the regimen. The 4 participants taking
LPV as per DBS test did not have any resistance muta-
tion detected to PI.
HIV incidence estimates
HIV incidence was estimated at 1.4 new cases per
100PY (95%CI: 0.8–2.0) when employing no measure of
ARV use, 1.1/100PY (95%CI: 0.6–1.7) using reported
ART, and 1.2/100PY (95%CI: 0.7–1.7) using ARV detec-
tion (Table 4). Incidence estimates were similar using
the 2 methods, with differences in point estimates con-
stituting a small fraction of the span of confidence inter-
vals. This analysis did not provide strong evidence for
preferring one measure over the other.
We estimated the maximum improvement in the pre-
cision of the incidence estimate that the inclusion of any
ARV use measure in the RITA may achieve. Assuming
an FRR of 0.5% for the RITA without an ARV measure
(substantially higher than our best estimate of 0.2%), the
complete elimination of residual false recency, and no
impact on MDRI, the relative standard error of the over-
all incidence estimate would decline from 20.8% to
17.9%. The potential benefit is therefore modest at best.
Discordance between self-report and ARV detection
Of the 1358 individuals with both self-report and ARV de-
tection information, 655 (48.2%) had ARVs detected and
reported being on ART, 58 (4.3%) had ARVs detected but
did not report being on ART (non-disclosure) and 52
(3.8%) reported being on ART but did not have ARVs de-
tected (non-adherence) (Additional file 2: Table S2).
There was non-disclosure of ART use in 8.1%
(95%CI: 6.3–10.4) of the participants. Non-disclosure
was higher at younger ages: 31.8% (95%CI: 15.5–54.3),
11.5% (95%CI: 7.9–16.3), 7.2% (95%CI: 4.6–11.1), 2.1%
(95%CI: 0.8–5.4), in individuals aged 15–19, 20–34, 35–44
and 45–59 years respectively (Chi2 test for trend p <
0.001).
Conversely, 7.4% (95%CI: 5.7–9.5) of the participants
reporting ART did not have ARVs detected, suggesting
poor recent adherence to ART. The proportion with dis-
cordance was higher in individuals 15–19 years com-
pared to individuals in the other group ages: 34.8%
(95%CI: 18.0–56.5) vs 7.4% (95%CI: 4.7–11.6), 8.3%
(95%CI: 5.2–12.9) and 2.7% (95%CI: 1.1–6.1) in individ-
uals aged 20–34, 35–44 and 45–59 years respectively
(Chi2 test for trend p < 0.001).
Among individuals who reported being on ART, me-
dian time since ART initiation was longer for individuals
who had ARVs detected compared to those for whom
ARVs were not detected: 33.8 vs 13.9 months.
Agreement between ART self-reported and ARV de-
tection was 91.9% (kappa = 0.84, 95%CI: 0.81–0.87).
There was no difference in the agreement between self-
report and ARV detection among male and female par-
ticipants, 92.0% (kappa = 0.84, 95%CI: 0.78–0.90) and
91.9% (kappa = 0.84, 95%CI: 0.80–0.87) respectively.
Agreement between the 2 methods of determining ART
exposure was lower in individuals aged 15–19 years:
77.6% (kappa = 0.50, 95%CI: 0.28–0.72) vs 92.6% (kappa
= 0.85, 95%CI: 0.80–0.89), 89.5% (kappa = 0.76, 95%CI:
0.69–0.83) and 96.8% (kappa = 0.93, 95%CI: 0.88–0.97)
in individuals aged 20–34, 35–44 and 45–59 years
respectively.
In multivariate logistic regressions, younger individuals
were at higher risk of discordant results (Table 5). Indi-
viduals younger than 45 years and particularly those
aged 15–19 years had the highest risk of all types of dis-
cordance (Table 5) while migrants were less likely to
have discordant results. Individuals with an education of
lower than secondary school who had reported ART
were more likely to test negative for ARVs than those
with higher levels of education.
Discussion
We found that estimates of antiretroviral coverage were
generally similar when using self-report and ARV detec-
tion to identify individuals on ART. Overall, there was
good concordance between self-report of ART use and de-
tection of ARVs in this study population. However, dis-
cordance was higher in individuals aged 15–19 years
suggesting higher proportions of poor recent adherence
and non-disclosure in young people. As a result, estimates
of ART coverage in this group were sensitive to the meas-
ure of ART exposure used. Individuals who had moved
residence in the last ten years were less likely to have dis-
cordance than permanent residents. The reason for this is
unclear and qualitative research is needed to explore
Table 4 HIV incidence estimates by sex and age without an
ARV measure, using ART self-report and using ARV detection
No ARV measure ART reported ARV detected
/100PY (95%CI) /100PY (95%CI) /100PY (95%CI)
Women 15–29 2.4 (1.2–3.7) 2.2 (1.1–3.5) 2.4 (1.2–3.6)
Men 15–29 0.9 (0.2–1.7) 0.7 (0.1–1.4) 0.7 (0.1–1.4)
Women 30–59 0.8 (0.0–1.7) 0.1 (0.0–0.8) 0.1 (0.0–0.8)
Men 30–59 0.6 (0.0–1.9) 0.6 (0.0–1.9) 0.6 (0.0–1.9)
All individuals 1.4 (0.8–2.0) 1.1 (0.6–1.7) 1.2 (0.7–1.7)
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differences regarding barriers to both disclosure and ad-
herence in these populations.
Rates of viral suppression were slightly higher using
ARV detection to identify those on ART. This finding
is expected since those with ARVs detected are likely to
be currently adherent to therapy. On the other hand,
individuals reporting ART with no detectable ARV are
likely to be poorly adherent and viral suppression was
very low in this group. Median time since ART initi-
ation was longer for individuals who had ARVs detected
which may be due to patients in this cohort struggling
with adherence particularly in the period immediately
after ART commencement, or because poorly adherent
patients default therapy. Estimates of suppression in ad-
olescents ranged widely depending on the method of
identifying ART exposure. The prevalence of resistance
among individuals on ART was also sensitive to the
method used to determine the denominator (higher for
ARV detection).
We found that the method of identifying ARV use had
little impact on incidence estimates. Including ARV use
in the RITA had only a modest impact on precision of
incidence estimates.
Measures of ARV use are frequently included in recent
infection testing algorithms (RITAs) on the intuition that
this would reduce the false recent rate (FRR) and im-
prove the precision of the incidence estimates. Context-
specific FRR estimates for an algorithm consisting of
LAg-Avidity EIA and viral load in a setting similar to the
study population have been estimated as low as 0.2%
[12]. Furthermore, benchmarking data are not available
for quantifying the impact of including a measure of
ARV use on the mean duration of recent infection
(MDRI) and FRR. It is therefore questionable whether
Table 5 Factors associated ART discordance using self-report and ARV detection in HIV-positive individuals
ART detected & not reported ART reported & not detected ART any discordance
(N = 1358) (N = 1358) (N = 1358)
OR 95%CI p a OR 95%CI p OR 95%CI p a OR 95%CI p OR 95%CI p aOR 95%CI p
Sex
Women 1 1 1 1 1 1
Men 0.6 0.3–1.2 0.15 0.6 0.3–1.3 0.19 1.6 0.9–2.8 0.15 1.6 0.9–2.9 0.14 1.0 0.6–1.6 0.97 1.0 0.7–1.7 0.83
Age group (years)
45–59 1 1 1 1 1 1
35–44 3.6 1.2–10.7 0.01 3.6 1.2–10.8 0.02 3.3 1.2–9.0 0.02 3.9 1.4–10.4 <0.01 3.6 1.7–7.5 <0.01 3.6 1.7–7.7 <0.01
20–34 3.3 1.2–9.5 <0.01 3.3 1.2–9.7 0.02 1.6 0.6–4.4 0.35 2.4 0.9–6.8 0.01 2.4 1.2–5.0 0.02 2.6 1.2–5.4 0.01
15–19 8.1 2.3–28.7 <0.01 8.1 2.3–28.6 <0.01 7.5 2.4–23.9 <0.01 11.5 3.5–38.1 <0.01 8.8 3.7–21.1 <0.01 9.4 3.9–22.8 <0.01
Marital status
Never Married 1 1 1
Married/
Living
Together
1.2 0.7–2.1 0.58 0.8 0.4–1.5 0.47 1.0 0.6–1.5 0.91
Divorced/
Separated/
Widowed
1.2 0.4–3.5 0.70 – – – 0.6 0.1–2.5 0.46 – – – 0.9 0.4–2.1 0.80 – – –
Education
2ary or more 1 1 1
1ary or less 0.6 0.4–1.1 0.11 – – – 1.8 0.0–3.2 0.05 2.0 1.1–3.7 0.03 1.0 0.7–1.5 0.85 – – –
Living area
Rural 1 1 1
Urban 0.4 0.2–1.1 0.07 – – – 0.9 0.5–1.9 0.82 – – – 0.7 0.4–1.1 0.14 – – –
Mobility
Resident 1 1 1 1 1 1
Visitor 0.8 0.2–3.4 0.78 0.8 0.2–3.4 0.77 0.9 0.2–3.8 0.87 0.8 0.2–3.3 0.72 0.8 0.3–2.3 0.75 0.8 0.3–2.2 0.64
Migrant 0.4 0.1–1.1 0.06 0.4 0.1–1.0 0.06 0.2 0.0–0.8 0.03 0.2 0.0–0.9 0.03 0.3 0.1–0.7 <0.01 0.3 0.1–0.6 <0.01
Employment
Employed 1 1 1
Unemployed 1.0 0.6–1.7 0.96 – – – 0.9 0.7–2.0 0.62 – – – 0.9 0.6–1.4 0.76 – – –
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such measures should be included in RITAs that already
contain a viral load measurement. However, with early
treatment becoming increasingly common and with
higher treatment coverage, larger numbers of individuals
on treatment but with detectable viral loads, continuing
to study the impact of ARV ascertainment on RITA
properties will be essential.
Based on these data, either method of ART exposure
ascertainment could be used for estimation of ART
coverage and viral suppression for the population as a
whole. However, we found that discordant results were
more common in younger individuals (9 folds higher
risk). This may skew estimates of ART coverage and viral
suppression, particularly in adolescent surveys. Based on
our data, both non-disclosure and poor recent adher-
ence are common in this group.
Use of a combination of methods may be useful for par-
ticular study questions: for example this would allow for
exploration of adherence patterns within a survey, and for
exploration of the relationship between adherence, viral
suppression and viral resistance. Including ARV detection
also allows for characterization of patterns of ART regi-
men use within the surveyed population.
This study has limitations. Adolescents formed a small
proportion of individuals in the sample, and we there-
fore lacked power for precise estimates in this group.
We did not have access to hospital and dispensing re-
cords, which would provide an objective confirmation of
long-term ART.
Conclusions
In conclusion, in KZN the method of identifying ARV
use had little impact on estimates of ART coverage, viral
suppression rate and HIV incidence. The method for de-
termining ART exposure should be selected based on
the primary study questions. Surveys focused on young
individuals, particularly adolescents, should consider
using the combination of self-report and ARV detection,
so that estimates are not skewed by non-disclosure or
poor adherence.
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